Trending Stories
Trending Stories
Creative Post
Wellness
A Popular “Brain Supplement” Ingredient Was Just Linked to Shorter Lifespan in Men
Tyrosine is a familiar name on nootropic and “brain fog” supplement labels, marketed for focus, stress resilience, and mental performance. A large new UK Biobank analysis found something considerably less
Weight Loss & Fitness
A Major Medical Group Says Obesity Treatment Success Shouldn’t Be Measured by Weight Loss Alone
The headline number attached to nearly every obesity drug trial is a weight-loss percentage — 15% at 68 weeks, 20% at a year, and so on. A new scientific statement
Popular Posts
Popular Category
Harnessing Emotion Through Color and Sound in Storytelling
- February 2, 2025
Welcome to Gemifys: A Journey into the World of Jewelry
- February 25, 2025
Skincare
New Non-Steroid Eczema Treatments in 2026: What’s Actually Approved vs. Still in Trials
Topical corticosteroids have been the default treatment for eczema flares for generations, and for good reason — they work, and they work fast. But long-term steroid use carries real risks
Skincare
Thiamidol, Malassezin, and Melasyl: The New Melasma Ingredients Challenging Hydroquinone
For decades, hydroquinone has been the default answer to melasma — the stubborn, symmetrical patches of facial pigmentation that flare with sun exposure and hormones and resist most things thrown
Wellness
BPC-157 and the FDA’s Peptide Panel Vote: What Actually Changed, and What Still Hasn’t
Updated September 2026: this post originally covered the FDA advisory committee’s compounding-access vote on BPC-157. Since then, the FDA has taken a separate enforcement action against online peptide vendors —
Weight Loss & Fitness
Is Berberine Really “Nature’s Ozempic”? What the Actual Evidence Shows
“Nature’s Ozempic” is a genuinely clever piece of marketing — it borrows the credibility and name recognition of a drug with real clinical trial data behind it and attaches it
Weight Loss & Fitness
Retatrutide’s Phase 3 Results Are In: The Highest Weight Loss Numbers Yet for This Drug Class
Every new GLP-1-class drug arrives with a comparison chart against Ozempic and Zepbound, and most of the time the differences are incremental. Retatrutide’s first full pivotal Phase 3 results are
Daily Newsletter
Get all the top stories from Papurfy to keep track.
[mc4wp_form id="448"]
